Multiple Sclerosis

Pharmacists bridge communication gaps and enhance shared decision-making.

Patients with multiple sclerosis being treated with glatiramer acetate have an increased risk of experiencing anaphylaxis.

Based on positive results from the HERCULES trial, the new designation will allow for more thorough regulatory review and development of the multiple sclerosis treatment.

Ocrelizumab (Ocrevus; Genentech) is used for the management and treatment of multiple sclerosis.

The approval marks the first and only twice yearly, health care professional-administrated injection for both forms of multiple sclerosis (MS).

Tocilizumab reduced relapses in 4 patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

Rather than “trial-and-erroring” transplants for patients, experts should instead select transplants that are precise, personalized, and predictable.

In a promising development in multiple sclerosis research, tolebrutinib delayed the onset of disability progression in patients with nrSPMS.

The bispecific CAR T-cell therapy for treatment of multiple sclerosis is the first to target both CD19 and CD20.

Predicting disease progression is essential to improve the health outcomes of patients with multiple sclerosis.

The findings show that inhibiting connexin 43 significantly improves multiple sclerosis symptoms in an experimental mouse model.

Multiple sclerosis is a debilitating disease affecting many Americans. Pharmacists can help patients control the symptoms that impact their quality of life.

In addition to racial inequities in access to care, socioeconomic challenges are very common for the specialty medications necessary in MS.

This is the largest dataset of pregnancy outcomes for an anti-CD20 therapy in MS, enabling a more comprehensive understanding of ocrelizumab’s safety.

Although this data seems to overwhelmingly suggest that cannabis use has negative impacts for individuals with multiple sclerosis (MS), listening to patients’ reasoning for using it is crucial.

Subcutaneous ocrelizumab can be delivered in approximately 10 minutes and deliver comparable clinical benefit and safety to the IV formulation.

Although resources were scarce for teams at smaller private practices, the pharmacists all agreed that patient care is always the priority.

There has been a general shift toward earlier treatment and less tolerance for clinically silent disease activity.

Although questions remain about ideal treatment strategies, consistent data have shown that patients should be treated early.

The results also showed that the PET scans could show damage to the individual’s brains, which was correlated with disability and fatigue.

Speakers in a presentation discuss a specific patient with MS who experienced urinary complications and the methods used to treat her.

Frexalimab demonstrated a favorable tolerability profile after approximately 1 year of treatment for individuals with relapsing disease.

Ofatumumab (Kesimpta; Novartis) demonstrated a sustained efficacy as a first-line, continuous treatment for patients recently diagnosed and treatment-naïve with relapsing multiple sclerosis.

Ocrelizumab (Ocrevus; Roche) is being investigated as a twice yearly 10-minute subcutaneous injection compared to the intravenous infusion formulation.

The platform is a first-of-its-kind therapeutic approach to promote remyelination among individuals with relapsing/remitting multiple sclerosis.